Table 1.

Heat shock protein 90 (Hsp90) inhibitor affecting the DNA repair.

Inhibitor	Derivatives	Structure	Pharmacokinetics (nM)	Clinical Study Stage	References
Geldanamycin (naturally derived from Streptomyces hygroscopicus)			GI50 = 1.0 × 10−1 nM; LC50 = 2.1 × 104 nM; Kd = 1.2 × 103 nM	Preclinical	[61,65,69]; www.medchemexpress.net
	17-AAG (17-allylamino-17-desmethoxygeldanamycin; tanespimycin)		IC50 = 5.0 × 101–1.0 × 104 nM	Phase I/II/III	[70,71,72,73,74,75,76,77,78]; www.clinicaltrials.gov; www.medchemexpress.net
	17-DMAG (17-dimethylaminoethylamino-17-demetoxygelanamycin; alvespimycin)		IC50 = 6.0 × 101–3.0 × 103 nM; Kd = 3.5 × 102 nM	Phase I/II	[72,77,79,80,81]; www.clinicaltrials.gov
PU-H71			IC50 = 5.0 × 101–3.0 × 102 nM	Phase I	[82,83,84]; www.clinicaltrials.gov
NVP-AUY922			IC50 = 1.3 × 101 nM (Hsp90α); IC50 = 2.1 × 101 nM (Hsp90β); GI50 = 2.0–4.0 × 101 nM; Kd = 1.7 nM	Phase I/II	[85,86,87]; www.medchemexpress.net; www.clinicaltrials.gov
Radicicol (naturally derived from Diheterospora chlamydosporia)			Kd = 1.9 × 101 nM; IC50 = 2.0 × 101 nM	Preclinical	[65]
STA9090 (Ganetespib)			IC50 = 1.0–5.0 × 101 nM	Phase I/II/III	[88,89,90,91]; www.clinicaltrials.gov; www.medchemexpress.net